Difficulty: Medium
Average Score: 93%
Practice
Tick the drug, inhibiting uncoating of the viral RNA:
Correct answer
B
Rationale
In the context of pharmacological lifespan treatment, the correct answer to the question regarding the drug that inhibits the uncoating of viral RNA is option B) Rimantadine. Rimantadine is a viral uncoating inhibitor that specifically targets influenza A virus by preventing the release of viral RNA into the host cell cytoplasm, thus hindering viral replication.
Acyclovir (option C) is an antiviral drug used mainly to treat herpes simplex virus and varicella-zoster virus infections by inhibiting viral DNA synthesis, not viral RNA uncoating. Vidarabine (option A) is an antiviral medication that inhibits DNA polymerase, primarily used for herpes simplex infections. Didanosine (option D) is a nucleoside reverse transcriptase inhibitor used in the treatment of HIV infections, not for inhibiting viral RNA uncoating.
In an educational context, understanding the mechanism of action of antiviral drugs is crucial for pharmacological lifespan treatment. Knowing how specific drugs target different stages of the viral replication cycle helps in selecting the most effective treatment for different viral infections. Rimantadine's mechanism of action in inhibiting viral RNA uncoating highlights its importance in treating influenza A virus infections. This knowledge is vital for healthcare professionals in making informed decisions about antiviral therapy to improve patient outcomes.
Acyclovir (option C) is an antiviral drug used mainly to treat herpes simplex virus and varicella-zoster virus infections by inhibiting viral DNA synthesis, not viral RNA uncoating. Vidarabine (option A) is an antiviral medication that inhibits DNA polymerase, primarily used for herpes simplex infections. Didanosine (option D) is a nucleoside reverse transcriptase inhibitor used in the treatment of HIV infections, not for inhibiting viral RNA uncoating.
In an educational context, understanding the mechanism of action of antiviral drugs is crucial for pharmacological lifespan treatment. Knowing how specific drugs target different stages of the viral replication cycle helps in selecting the most effective treatment for different viral infections. Rimantadine's mechanism of action in inhibiting viral RNA uncoating highlights its importance in treating influenza A virus infections. This knowledge is vital for healthcare professionals in making informed decisions about antiviral therapy to improve patient outcomes.